Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ingrezza
Marketing
Neurocrine data make case for timely movement disorder diagnosis
Neurocrine shared survey data showing how tardive dyskinesia affects patients' and caregivers' work, supporting its case for timely treatment.
Nick Paul Taylor
May 5, 2026 6:03am
Neurocrine's Ingrezza misses in cerebral palsy trial
Dec 23, 2025 10:20am
Neurocrine taps Wilson Phillips star for tardive dyskinesia push
May 6, 2025 11:16am
Neurocrine's Ingrezza guidance spooks investors
Feb 10, 2025 9:13am
FDA approves Neurocrine's Crenessity for genetic adrenal disease
Dec 16, 2024 11:26am
Neurocrine elevates BD chief to succeed founder and CEO
May 29, 2024 11:42am
